With PhII success, BridgeBio wades deeper into dwarfism drug debate
BridgeBio’s experimental drug designed to treat complications of achondroplasia, or dwarfism, greatly surpassed Wall Street expectations Monday morning in the final cohort of a Phase II trial, sending the company’s stock climbing high.
Infigratinib, an oral small molecule drug targeting the gene that causes dwarfism, induced roughly three-centimeters-per-year faster growth compared to baseline in 10 patients after six months, BridgeBio said Monday. The company has already started enrolling patients for a Phase III trial and will take this cohort’s dose — 0.25 mg/kg — into the pivotal study, CEO Neil Kumar told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.